[HTML][HTML] Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients

EA Semenova, M Kwon, K Monkhorst, JY Song… - Cell reports, 2016 - cell.com
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

EA Semenova, M Kwon, K Monkhorst, JY Song… - Cell Reports, 2016 - infona.pl
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

EA Semenova, M Kwon, R Bhaskaran, M Cozijnsen… - Cell Reports, 2016 - elibrary.ru
We thank members of the animal facility of the Netherlands Cancer Institute for maintaining
the mice; the division of animal pathology members Ellen Riem, Joost van Ooij, Lex de Vrije …

[PDF][PDF] Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

EA Semenova, M Kwon, K Monkhorst, JY Song… - Cell Reports, 2016 - core.ac.uk
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

[PDF][PDF] Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

EA Semenova, M Kwon, K Monkhorst, JY Song… - Cell …, 2016 - cyberleninka.org
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.

EA Semenova, MC Kwon, K Monkhorst, JY Song… - Cell Reports, 2016 - europepmc.org
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

[HTML][HTML] Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

EA Semenova, M Kwon, K Monkhorst, JY Song… - Cell Reports, 2016 - ncbi.nlm.nih.gov
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

[引用][C] Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

EA Semenova, M Kwon, K Monkhorst, JY Song… - Cell Reports, 2016 - cir.nii.ac.jp
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks
Metastatic Disease in Patients | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

[HTML][HTML] Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

EA Semenova, M Kwon, K Monkhorst, JY Song… - Cell Reports, 2016 - Elsevier
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

EA Semenova, MC Kwon, K Monkhorst… - Cell …, 2016 - pubmed.ncbi.nlm.nih.gov
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …